Navigation Links
Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill
Date:6/10/2008

CAMDEN, Maine, June 10 /PRNewswire-USNewswire/ -- Sen. Olympia Snowe (R-ME), member of the Senate Finance Committee, has cosponsored a Medicare bill -- S.3101 -- that includes pharmacy-related provisions to provide prompt payment of Medicare Part D prescription drug claims and delay the implementation of Medicaid reimbursement cuts for generic prescription drugs. In response, Dean Jacobs, RPh, owner of Waltz Pharmacy Inc. in Camden, ME and a member of the National Community Pharmacists Association (NCPA), issued the following statement:

"I wanted to personally thank Senator Olympia Snowe for cosponsoring S.3101, which is a health care bill that includes two provisions that ensure patients will continue to have access to community pharmacies in Maine and across America.

"The first provision ends the deliberately slow payment of Part D claims that force community pharmacies to maintain cash flow by taking out huge loans; while the second one delays the implementation of a fundamentally-flawed Medicaid reimbursement formula that forces community pharmacies to be reimbursed below actual generic prescription drug cost. Senator Snowe recognizes that community pharmacies are on the frontlines of our nation's health care system, and that these flawed pharmacy reimbursement policies were threatening to put community pharmacies out of business."

BACKGROUND:

Prompt Payment

In 2006, the first full year of Medicare Part D's implementation, five percent of America's community pharmacies permanently closed their doors. Ever since Part D's implementation on Jan. 1, 2006, community pharmacies have experienced cash-flow problems that have necessitated the need for loans in the tens to hundreds of thousands dollars. The pharmacy benefit managers (PBMs) responsible for administering the various Part D plans are paid by the government in advance, and could help remedy the problem, but rather than paying promptly, they choose to earn intere
'/>"/>

SOURCE National Community Pharmacists Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Maine Economic Study: Bush Medicare Cuts Undermine State and Local Economic, Jobs Base
2. Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine
3. Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays
4. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
5. Anthem Sponsors Healthy Kids Day at Maines YMCAs
6. Toms of Maine Helps Increase Access to Dental Care
7. Toms of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes
8. Farm Bill Provision Will Disrupt MaineCare Program
9. A Bright Future for Medicare Beneficiaries in Maine
10. Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses
11. Maine Natural Health Company Brings Omega-3 Benefits to Pets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 The Biofeedback ... a new distribution agreement with game development company ... the two groups to offer Zukor's Grind ... biofeedback and neurofeedback in European and international markets. ... developed expressly to be used as a biofeedback/neurofeedback ...
(Date:7/24/2014)... July 24, 2014 The North American air ... billion in 2014, and is expected to register a CAGR ... has been the biggest market for the air and missile ... U.S. market has witnessed budget cuts as well. , Browse ... defense radar market report, to get an idea of the ...
(Date:7/24/2014)... Steven Reinberg HealthDay ... Children covered by Medicaid, the publicly funded insurance program for ... more often than uninsured or privately insured youngsters, a U.S. ... than those with private insurance to visit for a reason ... survey conducted by the U.S. Centers for Disease Control and ...
(Date:7/24/2014)... News) -- Even though its use is often advised by ... does not help treat lower back pain, according to a ... was no more effective than a dummy pill for more ... Besides showing no effect in easing discomfort, the study also ... tied to back pain, nor did it improve patients, overall ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
Breaking Medicine News(10 mins):Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4
... Supported Efficacy, Safety and Tolerability of ... with Schizophrenia -, TOKYO and PRINCETON, N.J., ... Squibb Company (NYSE: BMY ) announced today ... the supplemental New,Drug Application for the atypical antipsychotic ...
... be lifesavers, study suggsts , TUESDAY, Nov. 6 (HealthDay ... artery bypass graft (CABG) surgery reduces a patient,s risk ... the Cleveland Clinic, included more than 5,200 patients who ... overall incidence of post-operative stroke one year after surgery ...
... To help raise awareness about the,prevalence of ... serving our country, TriWest Healthcare Alliance has contributed,$50,000 ... TBI. "According to the Department of Defense, ... members sustaining injuries in the Global War,on Terror ...
... Focus on Growth Businesses, LEHIGH VALLEY, Pa., Nov. ... Chemie AG are in advanced discussions over Wacker,s,purchase of ... Systems (WPS) and Air Products Polymers (APP), including APP,s,vinyl ... and,Wacker 35 percent. As for WPS, Wacker owns 80 ...
... 7 The Disabled American,Veterans (DAV) is commending ... the largest increase in funding for the Department ... on Congress and the,Administration to support this important ... Military Construction and Veterans Affairs Appropriations bill,calls for ...
... QED International Associates Inc.,administrator for the HealthShares(TM) ... today announced that effective at the,opening of trading ... GIVN ) will replace Dade Behring Holdings, ... Index, and Inverness Medical Innovations,(Amex: IMA ) ...
Cached Medicine News:Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 2Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 3Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 4Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 5Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 6Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 7Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 8Health News:TriWest Contributes $50,000 to Bob Woodruff Family Fund for Traumatic Brain Injury 2Health News:Air Products in Advanced Discussions With Wacker Over Polymers Business 2Health News:VA Budget Earns High Praise 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite, and the HealthShares(TM) Diagnostics Indexes 2
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
(Date:7/24/2014)... July 24, 2014 HIGHLIGHTS:Q2 2014 Results ... , Reported sales increased 3% to $701 million.  Sales ... rates added one percentage point to sales growth. , ... 6% in Applied and 1% in SAFC Commercial. , ... 2013, an increase of 13%.  Adjusted diluted EPS in Q2 ...
(Date:7/24/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro ® has been ... Capacity (DLCO) for phase 2 of the COPDGene ® ... Pulmonary Disease (COPD) ever undertaken.  COPD is now the ... affects millions of people worldwide.  In ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15
... and Company (NYSE: LLY ) announced that ... Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution ... study objective to restore testosterone levels to the normal ... testosterone. In addition, secondary outcomes showed that the treatment ...
... Wis., June 28, 2011 Novelos Therapeutics, Inc. ... for treatment and diagnosis of cancer, today announced that ... the defendants, motion to dismiss the putative federal securities ... Court for the District of Massachusetts in March 2010 ...
Cached Medicine Technology:Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 3Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 4Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 5Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 6Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 2Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 3
This kit has been designed for the quantitative,determination of total immunoreactive intact PTH (Total,Intact PTH) in blood samples. The Total Intact PTH,level is the sum of PTH (1-84) and N-t...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
Medicine Products: